drugset / Trial / NCT00132652

Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B

NCT00132652

Phase 3 Completed 240 enrolled Novartis Novartis Pharmaceuticals · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is being conducted to compare the safety and effectiveness of switching treatment from lamivudine to telbivudine (LdT) against continued lamivudine treatment. Results from patients who were taking lamivudine and then switched to telbivudine will be compared with the results from patients who continued on lamivudine alone.

Timeline

Start
2005-02
Primary completion
2006-12
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lamivudine Other / unclassified
Subject Telbivudine Small molecule